KMDA (Kamada Pharma) מכפיל P/S עתידי

Kamada Ltd. generates revenue from the supply of unique plasma-derived therapies for patients with rare pathologies, yet inelastic demand and significant pricing power allow the company to consistently increase drug prices. This daily price chart of the projected P/S, generated by the GURU.Markets system, reconciles these factors, while the value of 1.80 corresponds to the current metric. Production is carried out at its own plant, although late-stage tests are outsourced to external contractors.

Kamada Ltd. maintains a high authority in the production of sterile plasma-derived medicines, which drives a premium business valuation quantified by the ratio of current market capitalization to projected annual revenue. This metric determines the extent of the premium paid for future revenue growth, utilizing the forward P/S valuation history to identify critical points of asset overvaluation during periods of market volatility.